Using a new oral medication to prevent Type 1 Diabetes by targeting immune cells in the gut
Official title: Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes
Funded at Qrono, INC · NIH-11007750 · Data updated 2026-11-12
This study is testing a new oral medication called QR402 that aims to help people at risk of Type 1 Diabetes by using tiny particles to support the immune system and protect insulin-producing cells from being damaged.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Qrono, INC NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | July 22, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,500 |
| NIH project number | 1R41AI186895-01 |
| Project ID | NIH-11007750 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of developing Type 1 Diabetes, particularly those with early immunological signs of the disease.
✕Less likely to help
Patients who are already diagnosed with Type 1 Diabetes and require insulin therapy may not benefit from this preventative approach.
What this research studies
This research focuses on developing a novel oral medication, QR402, that targets specific immune cells in the intestines to prevent the destruction of insulin-producing cells in Type 1 Diabetes (T1D). The approach involves using nanoparticles to deliver an AMPK pathway agonist that promotes the development of tolerogenic dendritic cells, which are crucial for maintaining immune balance and preventing autoimmune responses. By enhancing the function of these immune cells, the research aims to restore tolerance and potentially halt the progression of T1D before it fully develops. This could provide a new preventative strategy for individuals at risk of T1D.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking preventative therapy for Type 1 Diabetes, reducing the incidence of the disease and improving the quality of life for at-risk individuals.
How similar studies have gone: While this approach is novel in targeting dendritic cells for T1D prevention, similar strategies in other autoimmune diseases have shown promise, indicating potential for success.
Where this research is happening
-
Qrono, INC
Pittsburgh, United States Active
Researchers
- Principal investigator: Cargill, Christina Paige — Qrono, INC
- Study coordinator: Cargill, Christina Paige
Related research
Other NIH-funded projects on the same topics.
-
Technological and Educational Approaches to Restore Hypoglycemia Awareness in Type 1 Diabetes
A two-arm study in adults with type 1 diabetes tests whether high-tech glucose control plus education or targeted training can help people regain awareness of low blood sugar.
-
Techniques for restoring awareness of low blood sugar in adults with type 1 diabetes
A randomized trial compares different approaches to help adults with type 1 diabetes recognize when their blood sugar is dipping so they can act quickly.
-
Treating impaired hypoglycemia awareness in type 1 diabetes with targeted education and technology
This study tests two treatment approaches to help adults with type 1 diabetes who often don’t realize their blood sugar is getting too low, using a mix of technology and education in two large groups.
-
Helping people with type 1 diabetes regain awareness of dangerous lows
A UK study tests two different approaches to help adults with type 1 diabetes recognize and respond to low blood sugar by comparing a high-tech insulin system with targeted education.
-
How the pancreas environment affects insulin-producing cells in type 1 diabetes
Researchers are studying how the surrounding tissue of the pancreas and its proteins influence insulin-producing cells in people with type 1 diabetes.
-
Understanding how hypoglycemia awareness changes in adults with type 1 diabetes and how automated insulin delivery and exercise might help restore it
This study will look at adults with type 1 diabetes to see how their awareness of low blood sugar evolves over time and whether automated insulin delivery and high-intensity exercise can help restore that awareness.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.